NEOADJUVANT CHEMOTHERAPY RESPONSE OF CERVICAL CANCER PATIENT STAGE IIB IN SANGLAH GENERAL HOSPITAL DENPASAR

Cervical cancer is a malignancy of the cervix caused by the human papillomavirus. The therapy administered on stage IIB cervical cancer is neoadjuvant chemotherapy. The purpose of this study was to determine the characteristics based on age, histopathological type, family history, parity, contraceptive history, chemotherapy response, and operability status in cases of cervical cancer stage IIB after neoadjuvant chemotherapy at Sanglah Hospital Denpasar. This study is a retrospective descriptive study sourced from the patient's medical record with a total sampling technique. The population and sample of this study were stage IIB cervical cancer patients post-neoadjuvant chemotherapy at Sanglah Hospital Denpasar for the 2020-2021 period according to the inclusion criteria. The results showed that there were 40 stage IIB cervical cancer patients with the highest number of cases aged 40-49 years (45%). The most common histopathological type was squamous cell carcinoma (85%). Patients without a family history of cervical cancer were 92.5%. Patients with parity > 2 were 52.5%. Patients with a history of contraceptive use were 65%. Good chemotherapy response was found in more than 70% of the patients. Patients with operable status were 57.5%.